LMND: Revenue Growing 79%, the Market Trading It Like a Broken Insurance Company

Lemonade is set to present at the Oppenheimer Technology Conference this Wednesday, August 12. The event itself isn't the story. The story is what the market is doing with a company posting 79% revenue growth while trading like one that can't figure out the insurance business.

The disconnect is the angle. The math is the proof.

1. Revenue growth is accelerating, not decelerating

Q2 2026 revenue came in at $294.4 million, up 79% year over year from $164.1 million. In-force premium — the committed annual premium stream from active policies, the best proxy for future revenue in insurance — reached $1.43 billion, up 32.5% year over year. That marks the 11th consecutive quarter of accelerating IFP growth.

The company raised its full-year revenue and gross earned premium guidance after the Q2 print. IFP growth is targeted at 33% for the full year.

So what? Revenue acceleration in insurance is the precursor to operating leverage. As fixed costs get spread across a larger premium base, margins expand. That's the structural path to profitability — and Lemonade is halfway there.

2. Adjusted EBITDA loss narrowed 54%. First profitable quarter targeted for Q4.

Adjusted EBITDA — earnings before interest, taxes, depreciation, and amortization, a proxy for core operating cash earnings — swung from a larger hole to a $19 million loss in Q2, a 54% improvement year over year. Management reaffirmed its target of delivering the first positive adjusted EBITDA quarter in Q4 2026, implying roughly $8 million in the hole quarter. Full-year 2026 adjusted EBITDA guidance sits at $48 million to $52 million, with a positive full-year 2027 target.

That timeline is the catalyst. Q4 2026 positive adjusted EBITDA would be the first time in the company's history the core operating model turns profitable in a quarter. Once that inflection hits, the narrative shifts from "when will they ever be profitable" to "how fast do margins expand from here."

3. The loss ratio improved, though it's not pristine

The gross loss ratio (the percentage of premiums paid out in claims) came in at 60%. That includes 7% of favorable prior-period development — in other words, past claims cost less than Lemonade originally reserved for — and 3% of catastrophe impact. Strip out the prior-period tailwind and the underlying ratio is closer to 67%, still a solid number for a growth-stage insurer but not yet at the level where bears would lose their case.

The loss adjustment expense ratio (the cost of administering claims, distinct from the actual claim payouts) was 5%, far below the industry average of roughly 9%. That's the AI-driven claims automation showing up in real dollars. The company's Blender AI system lets adjusters handle three times the claim volume they could before.

4. Operating expenses grew 41%, and that's the bear's only real argument

Excluding losses and loss adjustment expenses, operating expenses rose 41% year over year to $182 million. The company is spending heavily on growth — marketing spend has more than tripled due to AI-driven improvements in customer segmentation and pricing. The question is whether revenue growth can outrun spending.

The evidence so far says yes. Revenue grew 79% while operating expenses grew 41%. Gross profit hit $113 million, up 76% year over year, beating the 35% market estimate by nearly 4 percentage points. The operating expense line is still the variable to watch, but the gap between top-line growth and cost growth is widening in Lemonade's favor.

5. The valuation gap

Here's the number that matters: Lemonade trades at 4.2 times trailing sales. The company reported 79% revenue growth in the most recent quarter, guided for 33% IFP growth full-year, and is targeting its first profitable quarter less than four months away.

Progressive, the industry benchmark for profitable growth in personal lines insurance, trades at 1.4 times sales — but at 2.7% revenue growth. Lemonade's sales multiple is roughly 3x Progressive's while growing nearly 30x faster. That gap doesn't narrow on its own. It narrows when Q4 EBITDA hits positive and the market recalibrates from "growth story burning cash" to "profitable growth company."

The stock is down roughly 26% year-to-date, having fallen about 25% over the month prior to the Q2 earnings report. Piper Sandler cut its price target to $65 from $85 in March, citing the company's failure to yet hit its profitability target. The average Wall Street price target sits at $65, implying roughly 23% upside.

The consensus is treating a timeline question — when does EBITDA turn positive — as a whether question. The company has a four-month runway to answer it.

What to watch at Oppenheimer and after

Tim Bixby, the outgoing CFO transitioning to the board next year, will present at the conference. Nick Stead takes over as CFO on January 1, 2027. The transition timing means any detailed commentary on margin trajectory, reinsurance strategy, or the cost discipline needed to hit positive EBITDA in Q4 could carry outsized weight.

The company holds roughly $1.2 billion in cash and investments with no debt. Regulatory surplus (the capital buffer insurance companies must hold to meet solvency requirements) sits at $330 million, up from $290 million in Q1. The balance sheet is not a risk.

The break condition

The stock trades at 4.2x trailing sales while posting 79% revenue growth and targeting its first profitable quarter in Q4. If Q4 adjusted EBITDA comes in positive and Q3 shows continued narrowing — the path the company has laid out — the narrative shifts fast. Growth insurance companies that prove profitability re-rate sharply. The valuation gap between 4.2x sales at 79% growth and what the market pays for proven profitable insurers is the thesis in one number.

The risk is straightforward: if operating expenses accelerate faster than revenue growth, or if the loss ratio deteriorates in a severe weather year without the prior-period reserve releases to offset it, the EBITDA timeline slips and the bear case regains its footing. A full-year 2026 miss on the $48M–$52M adjusted EBITDA target would be the real problem.

But right now, the market is pricing Lemonade like a company that hasn't figured out the insurance business while the numbers say it's three quarters away from proving otherwise.